TARA•benzinga•
Protara Therapeutics To Give 2 Presentations And A Panel DiscussionFor The Ongoing Phase 2 Open-Label ADVANCED-2 Trial Of TARA-002 In Patients With Non-Muscle Invasive Bladder Cancer Will Be Featured At The Upcoming AUA 2025 Annual Meeting
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 10, 2025 by benzinga